LAUSR

Purpose: Using optical coherence tomography (OCT) angiography to assess the therapeutic effect of intravitreal anti–vascular endothelial growth factor on myopic choroidal neovascularization (CNV) by detecting the changes of shape, size, and flow area. Methods: Our prospective case series recruited consecutive patients with myopic CNV from January 2016 to August 2016. Intravitreal injections of ranibizumab were conducted on all patients. Patients received OCT angiography on 3 different follow-ups, including before treatment, 1 week after treatment, and 1 month after treatment. At each visit, we measured the best-corrected visual acuity, central macular thickness , greatest linear dimension of CNV, selected CNV area and flow area using OCT angiography. Results: This study involved 13 eyes of 12 patients, in which 9 eyes were of 9 women and 4 eyes were of 3 men, with mean age of 49.92 ± 14.79 years. Best-corrected visual acuity was significantly improved with decreased central macular thickness, greatest linear dimension, intraretinal fluid, or subretinal fluid 7 days or 30 days after treatment (All P < 0.05). Myopic CNV was presented as irregular or nearly round closed mass at the level of the outer retinal layer in all eyes at the initial visit. Thirty days after treatment, the size of selected CNV area and flow area were further decreased (t = 4.012, P = 0.003). Conclusion: Combined with OCT B-scan, OCT angiography, a new technique, could provide sensitive and intuitive images and quantitative analysis for monitoring and evaluating the therapeutic effect of intravitreal anti–vascular endothelial growth factor for myopic CNV.